SiO2 increases vial capacity for COVID-19 vaccines
Advanced materials company SiO2 Materials Science has increased the manufacturing capacity of its plastic medical-grade vials to help meet the demand for COVID-19 vaccines.
Affinity finds potent SARS-CoV-2 antibodies
Australian cancer therapeutics company Affinity Biosciences has discovered potent SARS-CoV-2 antibodies with potential therapeutic applications against the novel coronavirus.
Hansa licenses enzyme pretreatment for gene therapy
Hansa Biopharma has entered into an agreement with Sarepta Therapeutics for an exclusive worldwide license to develop and promote imlifidase as a pretreatment for gene therapy treatment of Duchenne muscular dystrophy and limb-girdle muscular dystrophy.
Inimmune gets grant for vaccine technology
Montana-based Inimmune received a $2 million grant from the U.S. National Institute for Allergy and Infectious Diseases to develop novel adjuvant and delivery systems for vaccines.
Luminex rolls out biological test platform to partners
Luminex has delivered the xMap Intelliflex system, a new version of its multiplexed biological test platform, to several life science partners.
New labs in Philadelphia due to gene, cell therapy demand
Real estate developer MRA Group is building lab spaces in Philadelphia to meet the region's growing demand for cell and gene therapy.
J&J's Ebola vaccine approved by EU
Johnson & Johnson announced that the European Commission granted marketing authorization for its Janssen Pharmaceutical Ebola vaccine regimen for the prevention of Ebola virus disease.
Lysogene partners with Weizmann Institute
Lysogene has inked a research agreement with Yeda Research and Development, the commercial arm of the Weizmann Institute of Science for novel gene therapy.
Intravacc, CimCure partner on cancer, COVID-19 vaccines
Intravacc has entered a strategic partnership with CimCure for in-licensing of CimCure's iBoost technology for cancer immunotherapy vaccines and a COVID-19 vaccine.
GoldenBiotech moves COVID-19 drug to phase II
Golden Biotechnology (GoldenBiotech), a Taiwanese-based biopharmaceutical company, has received U.S. Food and Drug Administration approval to begin a phase II clinical trial of antroquinonol on COVID-19 patients in the U.S.